The importance of differentiating ReoPro (c7E3 abciximab) induced thrombocytopenia from heparin-induced thrombocytopenia.
Davidson
S J
SJ
Turner
N
N
Clague
J R
JR
Oldershaw
P J
PJ
Burman
J F
JF
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology; D000925:Anticoagulants / Q000009:adverse effects* / Q000494:pharmacology; D003327:Coronary Disease / Q000097:blood / Q000628:therapy; D006493:Heparin / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000494:pharmacology; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010976:Platelet Count / Q000187:drug effects; D017713:Platelet Transfusion; D015607:Stents; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D000077284:Abciximab